To this end, we assessed the parent targeting antibody trastuzumab, conjugated to a fluorophore to track in vivo binding; trastuzumab‐IRDye800 was utilized as an imaging probe to identify if drug uptake in tumor co‐related to HER2 expression that was identified by flow cytometry and IHC. Here, ERBB2 is linked to neoplasm.